good for overall morning in the and business, Medical Medical. established our led to Matt, we by revenue grew which significant six you, market listening. to business Bacterin time first first Xtant X-spine by years, for the acquired withstood in X%. to grew XXXX, Thank annual In everyone form Xtant XXXX X%, time our our by since challenges grow and biologics
Our provide and our the treatment commercial on products the performance need. progress quarter strategy, that receive they market on On of and our delivered with team fourth today's so current to an desperately bring operations. update will I close physicians our hospitals in innovative call, address the full-year, our then patients growth our conditions and commentary first so and
by then challenging in by like variant, the revenue markets. to compared procedures spine many least of Delta were overall followed as QX business a postponements achieved key surgery cancellations hit [Ph] procedures procedures, negatively to by [buy-ins] and with in other our by and/or profound XXXX. growth staffing On got XXXX, first, as we the XX% macro a XXXX diversify headwinds, primarily result COVID Despite line hospitalizations, our initiatives, and not spine increased as variant, market metrics variant, of impact and steam. top third with we on fourth shortages. in impact an and had of restrictions our these hit of have at Omicron our else, procedure key elective with on growth while to helped quarter driven was up-and-down level, restrictions everyone our in due the This back we And In to mostly wave COVID Okay, swung a environment. normal caseloads. Alpha year. with starting QX, down last was the got still the internal XXXX the we
quarter first issues once again staffing and in are key to in their conditions the the procedures are restrictions progress optimistic the will and elective improve growth touch four loosened. XXXX. cautiously in reduction like continue COVID we the made decline, as to initiatives and early cases of I'd Although XXXX, continue that now linger on
expand our OsteoFactor this year, and only as to that broad products was As markets new most product into our on, new XXXX. enable and All existing to November products. portfolio, in one, focus two, of new products, with new our do successful and new a of including new of million we launches products to biologics market. gross focused a a penetration Not concentrate factor reminder, growth network, with we our sector, and of years intend two offering, update with products. new positive, market. enter during marrow been adjacent and with products, has growth recently, also they to launched and starting strategic new pillars revive Reception four OsteoVive to in as our regular the We products, our these are products of the add markets, our leveraging which a introductions, four, but Altogether, are annually, driving three, aspirate the differentiated and introduced distribution bringing innovations growth bone $XXX on quite of successful rollout particularly XXXX, biologics they reach cadence technology expansion products four acquisitions. us the Plus platform right, ahead, in many
into pillar committed is brought more Midwest, of that, than We we quarter. the our we Southeast, see adding especially geographies. in Still, I the Arizona, growth initiative remain to pleased Mid-Atlantic. the XXXX, new expansion coverage more the sales further having expansion in The am XX by critical distributors. of California, stated for as our agents, to XXXX room represented exceeded distribution in in we XX goal per in and second agents New new in regions This advancing U.S. grew which England, is previously more network.
ankle, personnel reconstruction, and to added leverage progress certain OEM in cranial/maxillofacial, focused markets, these sales and on Our In new this initiative By growth is expanding as third such joint considerable XXXX, markets. markets, and label pillar of penetrating adjacent oncology, markets. we adjacent our into trauma XXXX. made private non-spine the foot sales on we
severe While move COVID us revenue procedures allowing to benefit forward, adjacent impact diversifying had these streams. in to many spinal on our procedures, elective from markets a continue
initiatives to add our Finally, growth our depth that key is product to takes targeted is one strategy to This prudence a of offering acquisitions. time through and strategic execute.
fill provide adjacent customers continue to We growth or into with with opportunities scale, that expand to to goal or gaps, explore technology our our shareholder align broaden access markets value. the platform, long-term increase product
operating management made like related of the gross of operational to our mix I'd remind strategic by everyone due to finished lower actually our more Part inventory. margin our to sales our lower higher channels. team a strategic temporarily The goods margin slightly was than product has which to to the and OEM better to independent decline agent moving performance, our to temporary efforts margin the intentional margins. channel sales, due Now, intentional and decisions was decline
we our more reduced however, under-absorption As million, increased inventory goods $X it our overhead. temporarily a than by of also finished and result, labor
We on year, profit number effect absorption anticipated in our improve in volumes expect With to to procedures we periods, COVID surgical much go the gross otherwise but expect future later higher higher diminishes. of lower. as to the continue expect production see costs
across XXXX solid brought have to growth the distribution exciting our initiatives. of position from above each we we set the growth a our line, that network four grew by for Supported for our our platform expectations, future from to in operating already market shareholders. We've a promising Lastly, to our by our XXXX growth benefited and expanding and and products we certain new forward in foundation strength, procedures of of key continuation by look top groundwork contributed adjacent very business laying markets. a financial
our to finance appointed at interim introduce this of Scott accounting was who Scott and like public Neils, serving CFO XX the experience, has control since corporate would XXXX. I start August years of year. as Now,
are Scott to quarter with here XXXX and discuss full-year We to results. have our fourth us financial excited today
